BLCO / Bausch + Lomb Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Bausch + Lomb Announces Board Changes

Exhibit 99.1 Bausch + Lomb Announces Board Changes VAUGHAN, Ontario, Aug. 18, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpora

Bausch + Lomb Announces Second-Quarter 2025 Results

Exhibit 99.1 Bausch + Lomb Announces Second-Quarter 2025 Results •Revenue of $1.278 Billion •GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million •Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million •Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs t

Third Amendment to Credit and Guaranty Agreement by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto and other persons party thereto, JPMorgan Chase Bank, N.A. and Citibank, N.A., dated as of June 26, 2025.

Exhibit 10.1 Execution Version THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIRD AMENDMENT (this “Agreement”), dated as of June 26, 2025, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the 2025 Refinancing Term Lenders (as defined below) party hereto, the T

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 21, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

Indenture, dated as of June 26, 2025, by and among Bausch & Lomb Incorporated, Bausch+Lomb Netherlands B.V., the guarantors party thereto, Citibank, N.A., acting as trustee and as notes collateral agent and Citibank, N.A. London Branch, acting as paying agent, registrar, transfer agent and calculation agent.

Exhibit 4.1 Execution Version BAUSCH & LOMB INCORPORATED BAUSCH+LOMB NETHERLANDS B.V. €675,000,000 SENIOR SECURED FLOATING RATE NOTES DUE 2031 INDENTURE DATED AS OF JUNE 26, 2025 CITIBANK, N.A., AS TRUSTEE AND NOTES COLLATERAL AGENT CITIBANK, N.A., LONDON BRANCH AS PAYING AGENT, REGISTRAR, TRANSFER AGENT AND CALCULATION AGENT TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERE

Third Amendment to Credit and Guaranty Agreement by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto and other persons party thereto, JPMorgan Chase Bank, N.A. and Citibank, N.A., dated as of June 26, 2025.

EX-10.1 Exhibit 10.1 Execution Version THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIRD AMENDMENT (this “Agreement”), dated as of June 26, 2025, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the 2025 Refinancing Term Lenders (as defined below) party heret

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Exhibit 99.1 Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility VAUGHAN, Ontario, June 26, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, tod

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exa

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Commiss

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Exhibit 99.1 Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering VAUGHAN, Ontario, June 18, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collective

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exa

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Commiss

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exa

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Commiss

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Exhibit 99.1 Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement VAUGHAN, Ontario, June 10, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH + LOMB CORPORATION (Exact name of the registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH + LOMB CORPORATION (Exact name of the registrant as specified in its charter) Canada 001-41380 98-1613662 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Report For the Year ended December 31, 2024 Part I. Introduction This is the Conflict Minerals Report (“Report”) of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) for calendar year 2024, prepared and submitted in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Rule 13p-1, Form SD and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 19, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 19, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Form of Share Unit Award Agreement (Performance Restricted Share Units – Organic Revenue Growth) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Exhibit 10.1 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of CEO Share Unit Award Agreement (Performance Restricted Share Units – Relative TSR) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Exhibit 10.4 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Bausch + Lomb Announces First-Quarter 2025 Results

Exhibit 99.1 Bausch + Lomb Announces First-Quarter 2025 Results •Revenue of $1.137 Billion •GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million •Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million •Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 •Updating Full-Year 2025 Guidance to Reflect Estimated One-Tim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpor

Form of CEO Share Unit Award Agreement (Performance Restricted Share Units – Organic Revenue Growth) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Exhibit 10.2 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of Share Unit Award Agreement (Performance Restricted Share Units – Relative TSR) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Exhibit 10.3 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

Exhibit 99.1 Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance •Fourth-Quarter 2024 Financial Results ◦Revenue of $1.280 Billion ◦GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million ◦Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million ◦Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2025 Date of Report (Date of the earliest event reported) Bausch + Lom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2025 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Subsidiaries of Bausch + Lomb Corporation.

Exhibit 21.1 Subsidiary Information As of February 19, 2025 Entity Name Jurisdiction of Incorporation Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision S.A. Argentina AcuFocus Australia Pty. Ltd. Australia Bausch & Lomb (Australia) Pty Ltd Australia Bausch & Lomb Australia Holdings Pty Ltd. Australia Bausch & Lomb Gesellschaft m.b.H. Austria BAUSCH HEALTH LLC Belarus Bausch & Lomb Pharma S.A.

Insider Trading Policy

Exhibit 19.1 Insider Trading Policy Bausch + Lomb Corporation POLICY NO. 2 EFFECTIVE DATE PAGE NO 1 of 10 October 21, 2024 ISSUED BY: PREPARED BY: Legal Department Chief Legal Officer SUBJECT: APPROVED BY: Insider Trading and Reporting Board of Directors INSIDER TRADING POLICY A.PURPOSE The purpose of this Insider Trading Policy (the “Policy”) is to explain certain legal concepts and to implement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corporation

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Comm

Credit Agreement, dated as of May 10, 2022, as amended by the First Incremental Amendment, dated as of September 29, 2023 and by the Second Incremental Amendment dated as of November 1, 2024, by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto, Citibank, N.A., as revolving facility administrative agent and swingline lender and collateral agent thereto, Goldman Sachs Bank USA, as term facility administrative agent thereto, JPMorgan Chase Bank, N.A., as incremental term facilities administrative agent thereto, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Form 8-K filed with the SEC on November 1, 2024, which is incorporated by reference herein.

Exhibit 10.1 Execution Version SECOND INCREMENTAL AMENDMENT (this “Amendment”), dated as of November 1 2024, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the New Term Lenders party hereto and JPMorgan Chase Bank, N.A. (“JPM”), in its capacity as administrative

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Co

Bausch + Lomb Announces Third-Quarter 2024 Results

Exhibit 99.1 Bausch + Lomb Announces Third-Quarter 2024 Results •Revenue of $1.196 Billion •GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million •Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million •Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Soli

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of May 29, 2024.

Exhibit 10.1 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of May 29, 2024) 1. Purpose and Background The purposes of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpora

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of May 29, 2024.

Exhibit 99.1 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of May 29, 2024) 1. Purpose and Background The purposes of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Com

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value (2) Rule 457(c) and Rule 457(h) 14,000,000 (1) $15.

As filed with the Securities and Exchange Commission on August 1, 2024

As filed with the Securities and Exchange Commission on August 1, 2024 Registration No.

Amended and Restated Employee Matters Agreement, dated as of July 31, 2024, by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation.†

Exhibit 10.2 AMENDED AND RESTATED EMPLOYEE MATTERS AGREEMENT by and between BAUSCH HEALTH COMPANIES INC. and BAUSCH + LOMB CORPORATION Dated as of July 31, 2024 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS Section 1.01. Certain Definitions 1 ARTICLE II GENERAL ALLOCATION OF LIABILITIES; INDEMNIFICATION Section 2.01. Allocation of Employee-Related Liabilities 8 Section 2.02. Indemnification 9 Secti

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

Bausch + Lomb Announces Second-Quarter 2024 Results

Exhibit 99.1 Bausch + Lomb Announces Second-Quarter 2024 Results •Revenue of $1.216 Billion •GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million •Adjusted EBITDA (non-GAAP)1 of $209 Million •Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments •Raising Full-Year 2024

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizat

Bausch + Lomb Announces First-Quarter 2024 Results

Exhibit 99.1 Bausch + Lomb Announces First-Quarter 2024 Results •Revenue of $1.099 Billion •GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million •Adjusted EBITDA (non-GAAP)1 of $180 Million •Revenue Grew 18% as Reported and 20% on a Constant Currency1 Basis Compared to the First Quarter of 2023, Driven by Growth Across All Business Segments •Foreign Exchange Negatively Impacted

Form of Stock Option Grant Agreement (Non-Qualified Stock Option) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. ††

Exhibit 10.6 Bausch + Lomb Corporation Stock Option Grant Agreement (Nonqualified Stock Option) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(a) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby grants to you a Nonqualified Stock Option to purchase the number of Common Shares set forth below (

Brenton L. Saunders, originally filed as Exhibit 10.7 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on May 1, 2024, which is incorporated by reference herein. ††

Exhibit 10.7 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of Share Unit Award Agreement (Performance Restricted Share Units – Relative TSR) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. ††

Exhibit 10.4 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of Stock Option Grant Agreement (Non-Qualified Stock Option) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, by and between Bausch +Lomb Corporation and Brenton L. Saunders. ††

Exhibit 10.10 Bausch + Lomb Corporation Stock Option Grant Agreement (Nonqualified Stock Option) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(a) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby grants to you a Nonqualified Stock Option to purchase the number of Common Shares set forth below

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.11 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on May 1, 2024, which is incorporated by reference herein. ††

Exhibit 10.11 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Employment Agreement dated as of April 24, 2023, by and between Bausch + Lomb Corporation and Andrew Stewart. ††

Exhibit 10.2 BAUSCH + LOMB CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of April 11, 2023 (the “Effective Date”), by and between Bausch + Lomb Corporation, a corporation incorporated under the laws of Canada (the “Company”), and Andrew Stewart, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”). Where th

Form of Share Unit Award Agreement (Restricted Share Units) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. ††

Exhibit 10.5 Bausch + Lomb Corporation Share Unit Award Agreement (Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the “RSUs” or the “Aw

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizati

Employment Agreement dated as of April 24, 2023, by and between Bausch + Lomb Corporation and A. Robert D. Bailey. ††

Exhibit 10.1 BAUSCH + LOMB CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of April 11, 2023 (the “Effective Date”), by and between Bausch + Lomb Corporation, a corporation incorporated under the laws of Canada (the “Company”), and A. Robert D. Bailey, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”). Whe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpor

Form of Share Unit Award Agreement (Performance Restricted Share Units – Organic Revenue Growth) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. ††

Exhibit 10.3 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of Share Unit Award Agreement (Performance Restricted Share Units – Relative TSR) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, by and between Bausch +Lomb Corporation and Brenton L. Saunders. ††

Exhibit 10.8 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”)

Form of Share Unit Award Agreement (Restricted Share Units) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, by and between Bausch +Lomb Corporation and Brenton L. Saunders. ††

Exhibit 10.9 Bausch + Lomb Corporation Share Unit Award Agreement (Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the “Plan”), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the “RSUs” or the “Aw

COURTESY PDF OF PROXY STATEMENT

a 2024 PROXY STATEMENT Wednesday, May 29, 2024 | 10:00 a.m. Eastern Daylight T ime 2024 Notice of Annual Meeting and Proxy StatementOur Mission + Vision b Our Mission + Vision Our Values Our mission is simple, yet powerful: helping people see better to live better all over the world – that’s why we started and what we still strive for today. Through unwavering focus rooted in innovation, quality a

Message from the Chairman of the Board and Chief Executive Officer Notice of Annual Meeting of Shareholders Proxy Summary Election of Directors and Corporate Governance Election of Directors Corporate Governance Non-Employee Director Compensation Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2024 Date of Report (Date of the earliest event reported) Bausch + Lom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors Richard De Schutter to Retire from Board Following 2024 Annual Meeting

EX-99.1 Exhibit 99.1 Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors Richard De Schutter to Retire from Board Following 2024 Annual Meeting VAUGHAN, Ontario, Feb. 28, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Boa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corporation

Transition and Separation Agreement, dated as of November 6, 2023, between Joseph F. Gordon and Bausch + Lomb Corporation. ††.

Exhibit 10.28 TRANSITION AND SEPARATION AGREEMENT This TRANSITION AND SEPARATION AGREEMENT, dated as of November 6, 2023 (this “Agreement”), is entered into by and between Joseph F. Gordon (“Executive”) and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the “Company”). The Company and Executive are sometimes referred to individually herein as a “Party” and collectively

Subsidiaries of Bausch + Lomb Corporation.

Exhibit 21.1 Subsidiary Information As of February 21, 2024 Entity Name Jurisdiction of Incorporation Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision S.A. Argentina AcuFocus Australia Pty. Ltd. Australia Bausch & Lomb (Australia) Pty Ltd Australia Bausch & Lomb Australia Holdings Pty Ltd. Australia Bausch & Lomb Gesellschaft m.b.H. Austria BAUSCH HEALTH LLC Belarus Bausch & Lomb Pharma S.A.

Bausch + Lomb Corporation Financial Restatement Compensation Recoupment Policy.

Exhibit 97 BAUSCH + LOMB CORPORATION FINANCIAL RESTATEMENT COMPENSATION RECOUPMENT POLICY This Bausch + Lomb Corporation Financial Restatement Compensation Recoupment Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Bausch + Lomb Corporation (the “Company”) on July 24, 2023.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Exhibit 99.1 Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance •Fourth-Quarter 2023 Financial Results ◦Revenue of $1.173 Billion ◦GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million ◦Adjusted EBITDA (non-GAAP)1 of $231 Million ◦Revenue Grew 18% as Reported and 19% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2022, Dri

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 29, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or O

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (the “Company,” “Bausch + Lomb” or “B+L”), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset Purchase Agreement (as amended, modified or supplemented, the “Acquisition Agreement”) with Novartis Pharma AG and Novartis Finance Corpor

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organ

Separation Agreement, dated as of August 25, 2023, between Christina M. Ackermann and Bausch + Lomb Corporation, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed on November 1, 2023, which is incorporated by reference herein. ††.

Exhibit 10.1 SEPARATION AGREEMENT This SEPARATION AGREEMENT, dated as of August 25, 2023 (this “Agreement”), is entered into by and between Christina M. Ackermann (“Executive”) and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the “Company”). The Company and Executive are sometimes referred to individually herein as a “Party” and collectively as the “Parties.” WHEREAS

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

Exhibit 99.1 Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance •Revenues of $1.007 Billion •GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million •Adjusted EBITDA (non-GAAP)1 of $187 Million •Revenues Grew 7% as Reported and 8% on a Constant Currency1 Basis Compared to the Third Quarter of 2022, Driven by Growth in the Vision Care and Surgical S

Credit Agreement, dated as of May 10, 2022, as amended by the First Incremental Amendment, dated as of September 29, 2023, by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto, Citibank, N.A., as collateral agent thereto, Goldman Sachs Bank USA, as term facility administrative agent thereto and JPMorgan Chase Bank, N.A., as first incremental term facility administrative agent thereto, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Form 8-K filed with the SEC on September 29, 2023, which is incorporated by reference herein.

Exhibit 10.1 Execution Version FIRST INCREMENTAL AMENDMENT (this “Amendment”), dated as of September 29, 2023, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the New Term Lenders party hereto, Goldman Sachs Bank USA (“Goldman Sachs”), in its capacity as administ

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 29, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Org

Indenture, dated as of September 29, 2023, by and among Bausch + Lomb Corporation, the guarantors party thereto and Citibank, N.A., acting through its agency and trust division, as trustee and as notes collateral agent thereto, originally filed as Exhibit 4.1 to Bausch + Lomb Corporation’s Form 8-K filed with the SEC on September 29, 2023, which is incorporated by reference herein.

Exhibit 4.1 Execution Version BAUSCH + LOMB CORPORATION $1,400,000,000 8.375% SENIOR SECURED NOTES DUE 2028 INDENTURE DATED AS OF SEPTEMBER 29, 2023 CITIBANK, N.A., AS TRUSTEE, REGISTRAR, TRANSFER AGENT, PAYING AGENT AND NOTES COLLATERAL AGENT TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 51 Section 1.3 Rules of

Bausch + Lomb Completes Acquisition of XIIDRA® Poised for Significant Growth in Prescription Dry Eye Segment

Exhibit 99.1 Bausch + Lomb Completes Acquisition of XIIDRA® Poised for Significant Growth in Prescription Dry Eye Segment VAUGHAN, Ontario, Sept. 29, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-stero

Financial Statements and Exhibits, Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 14, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Co

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

Exhibit 99.1 Bausch + Lomb Announces Pricing of Senior Secured Notes Offering VAUGHAN, Ontario, Sept. 14, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has priced its previously announced offerin

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 11, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organization) (Co

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

Exhibit 99.1 Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA® VAUGHAN, Ontario, Sept. 11, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has launched an offering of

Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (in US Dollar thousand) For the six months ended June 30, 2023 and June 30, 2022

Exhibit 99.2 Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (Unaudited) (in US Dollar thousand) For the six months ended June 30, 2023 and June 30, 2022 Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (Unaudited) Statements of Assets Acquired and Liabilities Assumed Note As of June 30, 2023 (

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (the “Company,” “Bausch + Lomb” or “B+L”), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset Purchase Agreement (the “Acquisition Agreement”) with Novartis Pharma AG, Novartis Finance Corporation (together with Novartis Pharma AG,

Independent Auditors’ Report

Exhibit 99.1 Independent Auditors’ Report To Management of Novartis Pharma AG Report on the Audit of the Abbreviated Financial Statements Opinion We have audited the abbreviated financial statements related to the worldwide rights to Xiidra®, AcuStream, SAF312, and OJL332 (collectively, “the Assets”) of Novartis Group (‘Novartis’), which comprise abbreviated statements of assets acquired and liabi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2023 Date of Report (Date of the earliest event reported) Bausch + Lom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organ

Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook

Exhibit 99.1 Investor Contacts: Media Contacts: George Gadkowski T.J. Crawford [email protected] [email protected] (908) 705-2851 Allison Ryan [email protected] Lainie Keller (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-1198 Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook •Revenues of $1.035 Billion

Filing Fee Table

EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value (2) Rule 457(c) and Rule 457(h) 10,000,000(1) $19.

As filed with the Securities and Exchange Commission on August 2, 2023

S-8 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration F

Power of Attorney (included on the signature page of the Registration Statement)

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of April 24, 2023.

EX-99 Exhibit 99 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of April 24, 2023) 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

Form of Debt Indenture

EX-4.1 Exhibit 4.1 BAUSCH + LOMB CORPORATION, Issuer and [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt Securities BAUSCH + LOMB CORPORATION CERTAIN SECTIONS OF THIS INDENTURE RELATING TO SECTIONS 310 THROUGH 318, INCLUSIVE, OF THE TRUST INDENTURE ACT OF 1939: Trust Indenture Act Section Indenture Section 310(a) 7.09 310(b) 7.08 7.10 311(a) 7.13 311(b) 7.13 312(a) 5.01 5.02(a) 312(b) 5.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpora

Amendment to Executive Employment Agreement, dated as of June 9, 2023, by and between Bausch + Lomb Corporation and Joseph F. Gordon, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 2, 2023, which is incorporated by reference herein.††

Exhibit 10.1 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made as of June 9, 2023 by and between Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the “Company”), and Joseph F. Gordon, an individual (“Executive”). WHEREAS, the Company and Executive are parties to that certain Executive Employment Agreem

Description of Securities, originally filed as Exhibit 4.1 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 2, 2023, which is incorporated by reference herein.

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following summary describes the common shares of Bausch + Lomb Corporation (the “Company,” “we,” “us” or “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The following summary describ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

Stock and Asset Purchase Agreement by and among Bausch + Lomb Ireland Limited, Novartis Pharma AG, Novartis Finance Corporation and, for the limited purposes set forth therein, Bausch + Lomb Corporation, dated as of June 30, 2023, originally filed as Exhibit 2.1 to Bausch + Lomb Corporation’s Form 8-K filed with the SEC on July 7, 2023, which is incorporated by reference herein.

EX-2.1 Exhibit 2.1 STOCK AND ASSET PURCHASE AGREEMENT by and among Novartis Pharma AG, Novartis Finance Corporation, Bausch + Lomb Ireland Limited and Bausch + Lomb Corporation, solely for the purposes of Article 1 and Section 10.17 Dated as of June 30, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Construction 24 ARTICLE 2 PURCHASE AND SALE; LIABILITIES 25 2.1 Pur

Bausch + Lomb Will Acquire XIIDRA® Acquisition Represents Significant Opportunity for Growth in Prescription Dry Eye Segment

EX-99.1 Exhibit 99.1 News Release Bausch + Lomb Will Acquire XIIDRA® Acquisition Represents Significant Opportunity for Growth in Prescription Dry Eye Segment VAUGHAN, Ontario, June 30, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered into a definitive agreement with Novartis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizat

Bausch + Lomb Announces Key Leadership Changes

Exhibit 99.1 Investor Contacts: Media Contacts: Allison Ryan Lainie Keller [email protected] [email protected] (877) 354-3705 (toll free) (908) 927-1198 (908) 927-0735 Bausch + Lomb Announces Key Leadership Changes VAUGHAN, Ontario, June 1, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping peo

Form of Stock Option Grant Agreement (Non-Qualified Stock Option) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.7 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.7 Bausch + Lomb Corporation Stock Option Grant Agreement (Nonqualified Stock Option) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(a) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby grants to you a Nonqualified Stock Option to purchase the number of Common Shares set forth below (the “Option” or the “Award”). This Award

Form of Share Unit Award Agreement (Restricted Share Units) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.6 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.6 Bausch + Lomb Corporation Share Unit Award Agreement (Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the “RSUs” or the “Award”), payable in common shares of the Co

Form of Share Unit Award Agreement (Performance Restricted Share Units – Relative TSR) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.5 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.5 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”) in the target amount set forth below that

New Hire Stock Option Grant Agreement (Non-Statutory Stock Option) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (Brenton L. Saunders), originally filed as Exhibit 10.10 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.10 BAUSCH + LOMB CORPORATION FORM OF STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(a) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby grants to you an Option to purchase the number of Common Shares set forth below (the “Option” or the “Award”). This Award is subjec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizati

Employment Agreement dated as of August 1, 2022 by and between Bausch + Lomb Corporation and Yehia Hashad, originally filed as Exhibit 10.2 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.2 BAUSCH + LOMB CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of August 1, 2022 (the “Effective Date”), by and between Bausch + Lomb Corporation, a corporation incorporated under the laws of Canada (the “Company”), and Yehia Hashad, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”). Where the

Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance •Revenues of $931 Million •GAAP Net Loss Attribu

New Hire Restricted Share Unit Grant Agreement under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (Brenton L. Saunders), originally filed as Exhibit 10.9 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.9 Bausch + Lomb Corporation Form of Restricted Share Unit Award Agreement (Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the “Restricted Share Units” or the “Award”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpor

New Hire Share Unit Grant Agreement (Performance Restricted Share Units) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (Brenton L. Saunders), originally filed as Exhibit 10.8 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.8 Bausch + Lomb Corporation Form of Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Company’s 2022 Omnibus Incentive Plan, as amended and restated from time to time (the “Plan”), hereby awards to you Performance Restricted Share Units (“Share Uni

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of April 24, 2023.††

Exhibit 10.3 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of April 24, 2023) 1. Purpose and Background The purposes of the Amended and Restated 2022 Bausch + Lomb Corporation Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other servi

Form of Share Unit Award Agreement (Performance Restricted Share Units – Organic Revenue Growth) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.4 to Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 3, 2023, which is incorporated by reference herein. ††

Exhibit 10.4 Bausch + Lomb Corporation Share Unit Award Agreement (Performance Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to Section 7(c) of the Company’s 2022 Omnibus Incentive Plan (the “Plan”), hereby awards to you a Share Unit Award in the form of performance restricted share units (“PSUs”) in the target amount set forth below that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023

Exhibit 99.1 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] (877) 354-3705 (toll free) (908) 927-0735 Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals Mr. Bailey and Mr. Stewart Will Jo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

DEFINITIVE PROXY STATEMENT

Monday, April 24, 2023 4:00 p.m. Eastern Daylight T ime 2023 Notice of Annual Meeting and Proxy StatementA Legacy of Innovation “For more than a century and a half, we’ve been inspired and honored by our mission of helping people see better to live better . ” 1853 J. J. Bausch opens an optical goods store in Rochester, New Y ork. 1875 Bausch + Lomb begins microscope production. 1902 Bausch + Lomb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results •Fourth-Quarter 2022 Financial Results ◦Revenues of $996 Mil

Subsidiaries of Bausch + Lomb Corporation.

Exhibit 21.1 Subsidiary Information As of February 22, 2023 Entity Name Jurisdiction of Incorporation Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision S.A. Argentina AcuFocus Australia Pty. Ltd. Australia Bausch & Lomb (Australia) Pty Ltd Australia Bausch & Lomb Australia Holdings Pty Ltd. Australia Bausch & Lomb Gesellschaft m.b.H. Austria BAUSCH HEALTH LLC Belarus Bausch & Lomb Pharma S.A.

Amended and Restated Separation Agreement dated December 22, 2022 between Bausch + Lomb Corporation and Joseph C. Papa, originally filed as Exhibit 10.25 to Bausch + Lomb Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 22, 2023, which is incorporated by reference herein. ††

Exhibit 10.25 AMENDED AND RESTATED SEPARATION AGREEMENT This Amended and Restated Separation Agreement (the “Agreement”) is by and between Joseph C. Papa (the “Executive”) and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the “Company”). The Company and the Executive are sometimes referred to individually herein as a “Party” and collectively as the “Parties.” WHEREAS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corporation

Employment Agreement dated as of February 14, 2023 by and between Bausch + Lomb Corporation and Brenton L. Saunders, originally filed as Exhibit 10.35 to Bausch + Lomb Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 22, 2023, which is incorporated by reference herein.††

Exhibit 10.35 BAUSCH + LOMB CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of February 14, 2023 (the “Effective Date”), by and between Bausch + Lomb Corporation, a corporation incorporated under the laws of Canada (the “Company”), and Brenton L. Saunders, an individual (“Executive”) (hereinafter collectively referred to as “the parties”). Whe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of the earliest event reported) Bausch + Lom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Form of Matching Share Grant Agreement under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan originally filed as Exhibit 10.32 to Bausch + Lomb Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 22, 2023, which is incorporated by reference herein. ††

Exhibit 10.32 BAUSCH + LOMB CORPORATION MATCHING RESTRICTED SHARE UNIT AWARD AGREEMENT (MATCHING SHARE PROGRAM UNITS) (Bausch + Lomb Corporation 2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the “Company”), pursuant to the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the “Plan”), hereby awards to you a Restricted Share Unit Award in the form of matching share units (the “Matchi

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2023 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023 Mr. Saunders Brings More Than 25 Years of Health Care Leadership to Bausch + Lomb

Exhibit 99.1 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] (877) 354-3705 (toll free) (908) 927-0735 Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023 Mr. Saunders Brings More Than 25 Years of Health Care

BLCO / Bausch + Lomb Corp / Valeant Pharmaceuticals International, Inc. - SC 13G Passive Investment

SC 13G 1 d459284dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bausch + Lomb Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 071705107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Orga

Bausch + Lomb Amends CEO Separation Agreement

Exhibit 99.1 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] (877) 354-3705 (toll free) (908) 927-0735 Bausch + Lomb Amends CEO Separation Agreement VAUGHAN, Ontario, Dec. 22, 2022 ? Bausch + Lomb Corporation (NYSE/TSX: BLCO) (?Bausch + Lomb? or the ?Company?), a leading global eye

Form of Restricted Share Unit Award Agreement pursuant to the 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.3 to Bausch + Lomb Corporation’s Form 10-Q filed with the SEC on November 2, 2022, which is incorporated by reference herein. ††

Exhibit 10.3 Bausch + Lomb Corporation Form of Restricted Share Unit Award Agreement (Restricted Share Units) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the ?Company?), pursuant to Section 7(c) of the Company?s 2022 Omnibus Incentive Plan (the ?Plan?), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the ?Restricted Share Units? or the ?Award?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Co

Bausch + Lomb Announces Third-Quarter 2022 Results

Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces Third-Quarter 2022 Results ?Third-Quarter 2022 Financial Results ?Revenues of $942 Million ?GAAP Net L

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organ

Separation Agreement dated July 19, 2022 between Bausch + Lomb Corporation and Joseph C. Papa, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Form 10-Q filed with the SEC on November 2, 2022, which is incorporated by reference herein. ††

Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the ?Agreement?) is by and between Joseph C. Papa (the ?Executive?) and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the ?Company?). The Company and the Executive are sometimes referred to individually herein as a ?Party? and collectively as the ?Parties.? WHEREAS, the Executive is currently employed as the

Form of Executive Committee Retention Program Letter Agreement, originally filed as Exhibit 10.2 to Bausch + Lomb Corporation’s Form 10-Q filed with the SEC on November 2, 2022, which is incorporated by reference herein. ††

Exhibit 10.2 400 Somerset Corporate Blvd. Bridgewater, NJ 08807 908-927-1400 July 27, 2022 [Name] Dear [Name]: The Board of Directors and I recognize that the CEO leadership transition creates some uncertainty for our company and the remaining leadership team during this transitional period. We have built a strong Executive Committee team and each of you is critical to the organization, your peopl

Bausch + Lomb Announces Second-Quarter 2022 Results

EX-99.1 2 ex991q2-2022.htm EX-99.1 Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces Second-Quarter 2022 Results •Second-Quarter 2022 Financial Results

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpora

Certificate of the Chief Executive Officer of Bausch + Lomb Corporation pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph C. Papa, Chief Executive Officer of Bausch + Lomb Corporation (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: 1. The Quarterly Report

Certificate of the Chief Financial Officer of Bausch + Lomb Corporation pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sam Eldessouky, Executive Vice-President and Chief Financial Officer of Bausch + Lomb Corporation (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

Bausch + Lomb Provides Leadership Update

Exhibit 99.1 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] (877) 354-3705 (toll free) (908) 927-0735 Bausch + Lomb Provides Leadership Update VAUGHAN, Ontario, July 20, 2022 ? Bausch + Lomb Corporation (NYSE/TSX: BLCO) (?Bausch + Lomb? or the ?Company?), a leading global eye healt

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors

Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors VAUGHAN, Ontario, June 23, 2022

Amended and Restated Director Appointment and Nomination Agreement between Bausch + Lomb Corporation and the Icahn Group dated as of June 21, 2022, originally filed as Exhibit 10.1 to Bausch + Lomb Corporation’s Form 8-K filed with the SEC on June 23, 2022, which is incorporated by reference herein.

EX-10.1 2 dp175752ex1001.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version REDACTED Certain identified information, indicated by [*****], has been omitted pursuant to Item 601(b)(10) because it is (i) not material and (ii) contains personal information. AMENDED AND RESTATED DIRECTOR APPOINTMENT AND NOMINATION AGREEMENT This Amended and Restated Director Appointment and Nomination Agreement, dated as

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41380 Bausch + Lomb Corpor

Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance

Exhibit 99.1 Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance ? First-Quarter 2022 Financial Resul

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2022 Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporation or Organizat

BAUSCH + LOMB CORPORATION (a business of Bausch Health Companies Inc.) INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Exhibit 99.1 BAUSCH + LOMB CORPORATION (a business of Bausch Health Companies Inc.) INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 F-2 Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 F-3 Condensed Consolidated Statements of Comprehensive Loss for the three

Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022

Exhibit 99.2 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (908) 927-1198 Allison Ryan [email protected] Kristy Marks (877) 354-3705 (toll free) [email protected] (908) 927-0735 (908) 927-0683 Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022 VAUGHAN, Ontario, May 16, 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 17, 2022 (May 16, 2022) Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporati

Amended Articles of Bausch + Lomb Corporation, originally filed as Exhibit 3.1 to Bausch + Lomb Corporation’s Form 8-K filed with the Commission on May 10, 2022.

Exhibit 3.1 Innovation, Science and Economic Development Canada Corporations Canada Innovation, Sciences et D?veloppement ?conomique Canada Corporations Canada Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les soci?t?s par actions Bausch + Lomb Corporation Corporate name / D?nomination sociale 1227928-2 Corporation number / Num?ro de soci?t

Amended By-laws of Bausch + Lomb Corporation, originally filed as Exhibit 3.2 to Bausch + Lomb Corporation’s Form 8-K filed with the Commission on May 10, 2022.

Exhibit 3.2 BY-LAW NO. 2022-1 a by-law relating generally to the transaction of the business and affairs of BAUSCH + LOMB CORPORATION (the ?Corporation?) ARTICLE 1 DEFINITIONS AND PRINCIPLES OF INTERPRETATION 1.1 Definitions In this By-law and all other By-laws of the Corporation, unless the context indicates otherwise: (a) ?Act? means the Canada Business Corporations Act or any statute which may

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 (May 5, 2022) Date of Report (Date of the earliest event reported) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 001-41380 98-1613662 (State or Other Jurisdiction of Incorporatio

Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent

EX-10.1 4 d322845dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AND GUARANTY AGREEMENT dated as of May 10, 2022 among BAUSCH + LOMB CORPORATION, as the Borrower, CERTAIN SUBSIDIARIES OF BAUSCH + LOMB CORPORATION, as Subsidiary Guarantors, THE FINANCIAL INSTITUTIONS PARTY HERETO, as Lenders and Issuing Banks, CITIBANK, N.A., as Revolving Facility Administrative Agent and Swingline Lender,

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan

EX-99 4 dp172625ex99.htm EXHIBIT 99 Exhibit 99 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN 1. Purpose and Background The purposes of the 2022 Bausch + Lomb Corporation Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Company and its Subsidiar

35,000,000 Common Shares Bausch + Lomb Corporation

424B4 1 d178785d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-262148 PROSPECTUS 35,000,000 Common Shares Bausch + Lomb Corporation This is an initial public offering of common shares of Bausch + Lomb Corporation. All of our common shares to be sold in this offering are currently held by 1261229 B.C. Ltd. (the “selling shareholder”), a wholly-owned subsidia

As filed with the Securities and Exchange Commission on May 5, 2022

As filed with the Securities and Exchange Commission on May 5, 2022 Registration No.

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value (2) Rule 457(c) and Rule 457(h) 28,000,000(1) $18(2) $504,000,000(2) 0.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Bausch + Lomb Corporation (Exact Name of Registrant as Spec

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Bausch + Lomb Corporation (Exact Name of Registrant as Specified in Its Charter) Canada 98-1613662 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 520 Applewood Crescent Vaughan,

[Signature Page Follows]

May 3, 2022 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E., Room 4415 Washington, D.C. 20549-4631 Attn: Mr. David Gessert Mr. Tim Buchmiller Re: Bausch + Lomb Corporation Registration Statement on Form S-1 Registration No. 333-262148 Dear Messrs. Gessert and Buchmiller: Pursuant to Rule 461 under the Securities Act of 19

Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4

Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 May 3, 2022 Division of Corporation Finance Office of Life Sciences U.

Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022

Exhibit 10.2 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. ARRANGEMENT AGREEMENT BETWEEN BAUSCH HEALTH COMPANIES INC. - AND - BAUSCH + LOMB CORPORATION - AND - 1261229 B.C. LTD. - AND - 12279967 CANADA LTD. - AND - 12283778 CANADA LTD. Made as

As filed with the Securities and Exchange Commission on April 28, 2022

Table of Contents As filed with the Securities and Exchange Commission on April 28, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) (2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common shares 457 (a) $866,000,000 $92.

Michael Kaplan

Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 April 28, 2022 Re: Bausch + Lomb Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed March 31, 2022 File No. 333-262148 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences U.S. Securitie

Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022

Exhibit 10.4.1 AMENDMENT TO TAX MATTERS AGREEMENT This AMENDMENT NO. 1 TO TAX MATTERS AGREEMENT, dated as of April 28, 2022 (this ?Amendment?), is by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, Canada (?Parent?), and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (?SpinCo?). Parent and SpinCo are

Letter Agreement among Bausch + Lomb Corporation, Bausch Health Companies Inc. and Solta Medical Corporation dated as of March 30, 2022, originally filed as Exhibit 10.24 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein.

Exhibit 10.24 BAUSCH HEALTH COMPANIES INC. 2150 St. Elz?ar Blvd. West Laval, Qu?bec, Canada H7L 4A8 March 30, 2022 Bausch + Lomb Corporation 400 Somerset Corporate Blvd Bridgewater, NJ 08807, USA Attention: General Counsel Solta Medical Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 5X3 Attention: General Counsel Re: Potential Separation of Solta Medical Reference is made to (i) M

Director Appointment and Nomination Agreement between Bausch + Lomb Corporation and the Icahn Group dated as of April 28, 2022

Exhibit 10.25 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. DIRECTOR APPOINTMENT AND NOMINATION AGREEMENT This Director Appointment and Nomination Agreement, dated as of April 28, 2022 (this ?Agreement?), is by and among the persons and entitie

Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022

Exhibit 10.1.1 Executive Version AMENDMENT TO MASTER SEPARATION AGREEMENT This AMENDMENT NO. 1 TO MASTER SEPARATION AGREEMENT, dated as of April 28, 2022 (this ?Amendment?), is by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, Canada (?Parent?), and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (?Sp

Michael Kaplan

Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 April 28, 2022 Re: Bausch + Lomb Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed March 31, 2022 File No. 333-262148 Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchang

LETTER

United States securities and exchange commission logo April 27, 2022 Joseph C. Papa Chief Executive Officer Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 Re: Bausch + Lomb Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed March 31, 2022 File No. 333-262148 Dear Mr. Papa: We have reviewed your amended registration statement and have the foll

LETTER

United States securities and exchange commission logo April 13, 2022 Joseph C. Papa Chief Executive Officer Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 Re: Bausch + Lomb Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed March 31, 2022 File No. 333-262148 Dear Mr. Papa: We have reviewed your amended registration statement and have the foll

Form of Common Share Certificate, originally filed as Exhibit 4.1 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein

Exhibit 4.1 SHARES Tills certifies that ??12345678901 * 5868444 .1 2345678901 ........... *** 12345678901 **?? * ?????????? * 8901 FULLY PAID AND NON-ASSESSABLE ....12345678901 ????????? ? S868444 ? OOTOR0606007 ? 1234 BAUSCH + L OMB CORPORATION ? ~? WITHOUT PAR VALUE BAUSCH + LOMB PAID AND NON-ASSESSABLE COMMON SHARES 44 ? OOTOR0606007 ? 12345678901 FULLY CH + LOMB CORPORATI ON ? PROOF ? 58 VALUE

Form of Stock Option Grant Agreement (Founders Grant) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.22 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.22 BAUSCH + LOMB CORPORATION FORM OF STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION ? FOUNDER GRANT) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the ?Company?), pursuant to Section 7(a) of the Company?s 2022 Omnibus Incentive Plan (the ?Plan?), hereby grants to you an Option to purchase the number of Common Shares set forth below (the ?Option? or the ?Award?). This

Filing Fee Table

EX-FILING FEES 22 d178785dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggre

Subsidiaries of the registrant

Exhibit 21.1 ENTITY NAME JURISDICTION Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision SA Argentina Bausch & Lomb (Australia) Pty Ltd Australia Bausch & Lomb Australia Holdings Pty Ltd. Australia Bausch & Lomb GmbH Austria Bausch Health LLC Belarus Bausch & Lomb Pharma S.A. Belgium BL Ind?stria ?tica Ltda. Brazil 9079-8851 Qu?bec, Inc. Canada Beijing Bausch & Lomb Eyecare Company Ltd. China

Loan Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of January 1, 2022, originally filed as Exhibit 10.10 to Bausch + Lomb Corporation’s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein

Exhibit 10.10 Loan Agreement 757 between BAUSCH HEALTH COMPANIES INC. as Lender and BAUSCH + LOMB CORPORATION as Borrower This Loan Agreement (this ?Agreement?) is dated as of the Effective Date (as defined below), between BAUSCH HEALTH COMPANIES INC. (?Lender?), a corporation continued under the laws of the Province of British Columbia and BAUSCH + LOMB CORPORATION (?Borrower?), a corporation org

Employee Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.6 EMPLOYEE MATTERS AGREEMENT by and between BAUSCH HEALTH COMPANIES INC. and BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS Section 1.01. Certain Definitions 1 ARTICLE II GENERAL ALLOCATION OF LIABILITIES; INDEMNIFICATION Section 2.01. Allocation of Employee-Related Liabilities 9 Section 2.02. Indemnification 10 Section 2.03. Agency Tra

Form of Director Restricted Share Unit Award Agreement (Annual Grant) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.11 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.11 INSTRUMENT OF GRANT?DIRECTOR RESTRICTED SHARE UNITS (ANNUAL GRANTS) Unitholder: Date of Grant: Number of Units: Bausch + Lomb Corporation (the ?Company?) hereby grants to the Unitholder named above (the ?Unitholder?), the number of restricted share units (the ?Units?) of the Company set forth above, in accordance with and subject to the terms, conditions and restrictions of this Unit

Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph F. Gordon dated as of January 3, 2022, originally filed as Exhibit 10.21 to Bausch + Lomb Corporation’s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.21 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT This assignment, assumption and amendment agreement (the ?Agreement?) is dated January 3, 2022 among Bausch Health Companies Inc., a corporation a corporation incorporated under the British Columbia Business Corporations Act (the ?Assignor?), Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the ?Assignee?) and

Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Sam A. Eldessouky dated as of January 3, 2022, originally filed as Exhibit 10.19 to Bausch + Lomb Corporation’s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.19 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT This assignment, assumption and amendment agreement (the ?Agreement?) is dated January 3, 2022 among Bausch Health Companies Inc., a corporation a corporation incorporated under the British Columbia Business Corporations Act (the ?Assignor?), Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the ?Assignee?) and

Form of Director Restricted Share Unit Award Agreement (Elective Grant) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.12 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.12 INSTRUMENT OF GRANT?DIRECTOR RESTRICTED SHARE UNITS (ELECTIVE GRANTS) Unitholder: Date of Grant: Number of Units: Bausch + Lomb Corporation (the ?Company?) hereby grants to the Unitholder named above (the ?Unitholder?), the number of restricted share units (the ?Units?) of the Company set forth above, in accordance with and subject to the terms, conditions and restrictions of this Un

Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.1 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. MASTER SEPARATION AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page SCHEDULES iv EXHIBITS iv ARTICLE

Registration Rights Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.5 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT, dated as of March 30, 2022 (this ?Agreement?), is made by and between Bausch Health Companies Inc., a corporation conti

Real Estate Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.8 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. REAL ESTATE MATTERS AGREEMENT This REAL ESTATE MATTERS AGREEMENT, dated as of March 30, 2022 (this ?Agreement?), is by and between Bausch Health Companies Inc., a corporation continued

Intellectual Property Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.7 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. INTELLECTUAL PROPERTY MATTERS AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS

Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.9 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein. ††

EX-10.9 10 d178785dex109.htm EX-10.9 Exhibit 10.9 BAUSCH + LOMB CORPORATION 2022 OMNIBUS INCENTIVE PLAN 1. Purpose and Background The purposes of the 2022 Bausch + Lomb Corporation Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Company and its Subsid

As filed with the Securities and Exchange Commission on March 30, 2022

Table of Contents As filed with the Securities and Exchange Commission on March 30, 2022 Registration No.

Transition Services Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.3 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. TRANSITION SERVICES AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE

Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022

Exhibit 10.4 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. TAX MATTERS AGREEMENT between BAUSCH HEALTH COMPANIES INC., on behalf of itself and the members of the Parent Group and BAUSCH + LOMB CORPORATION, on behalf of itself and the members of

Form of Restricted Stock Unit Award Agreement (Founders Grant) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, originally filed as Exhibit 10.23 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.23 BAUSCH + LOMB CORPORATION FORM OF RESTRICTED SHARE UNIT AWARD AGREEMENT (RESTRICTED SHARE UNITS ? FOUNDER GRANT) (2022 Omnibus Incentive Plan) Bausch + Lomb Corporation (the ?Company?), pursuant to Section 7(c)(v) of the Company?s 2022 Omnibus Incentive Plan (the ?Plan?), hereby awards to you a Restricted Share Unit Award in the form of restricted share units (the ?Restricted Share U

Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Christina M. Ackermann dated as of January 3, 2022, originally filed as Exhibit 10.20 to Bausch + Lomb Corporation’s Registration on Statement Form S-1 filed on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.20 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT This assignment, assumption and amendment agreement (the ?Agreement?) is dated January 3, 2022 among Bausch Health Companies Inc., a corporation a corporation incorporated under the British Columbia Business Corporations Act (the ?Assignor?), Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the ?Assignee?) and

Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph Papa dated as of January 3, 2022, originally filed as Exhibit 10.18 to Bausch + Lomb Corporation’s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. ††

Exhibit 10.18 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT This assignment, assumption and amendment agreement (the ?Agreement?) is dated January 3, 2022 among Bausch Health Companies Inc., a corporation a corporation incorporated under the British Columbia Business Corporations Act (the ?Assignor?), Bausch + Lomb Corporation, a company incorporated under the laws of Canada (the ?Assignee?) and

Form of Indemnification Agreement, originally filed as Exhibit 10.17 to Bausch + Lomb Corporation’s Form S-1/A filed with the SEC on April 28, 2022, which is incorporated by reference herein.

Exhibit 10.19 INDEMNITY AGREEMENT THIS AGREEMENT is made as of ?, 202? BETWEEN: BAUSCH + LOMB CORPORATION, a corporation existing under the Canada Business Corporations Act (the ?Corporation?) - and - , an individual resident in , (the ?Indemnified Party?) RECITALS: A. The Indemnified Party is, has been or, at the request of the Corporation, proposes to become, a director or officer of the Corpora

Form of Articles of Bausch + Lomb to be effective upon its continuance under the BCBCA

Exhibit 3.2 Incorporation Number: ? ARTICLES OF BAUSCH + LOMB CORPORATION PROVINCE OF BRITISH COLUMBIA BUSINESS CORPORATIONS ACT TABLE OF CONTENTS Page PART 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 2 PART 2 SHARES AND SHARE CERTIFICATES 2 2.1 Authorized Share Structure 2 2.2 Form of Share Certificate 2 2.3 Shareholder Entitled

Consent of Sarah B. Kavanagh

Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

Form of Underwriting Agreement

Exhibit 1.1 [*] Shares BAUSCH + LOMB CORPORATION COMMON SHARES UNDERWRITING AGREEMENT [*], 202[*] [*], 2022 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 Ladies and Gentlemen: 1261229 B.C. Ltd., a limited company incorporated under the laws of the Provinc

Consent of Nathalie Bernier

Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

Consent of Andrew C. von Eschenbach

Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

Form of Articles of Bausch + Lomb to be effective at closing

Exhibit 3.1 Canada Business Corporations Act (CBCA) FORM 7 RESTATED ARTICLES OF INCORPORATION (Section 180) 1 - Corporate name Bausch + Lomb Corporation 2 - Corporation number 1227928-2 3 ? The province or territory in Canada where the registered office is situated (do not indicate the full address) British Columbia 4 ? The classes and any maximum number of shares that the corporation is authorize

Consent of Russel C. Robertson

Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

Michael Kaplan

Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 January 13, 2022 Re:??Bausch + Lomb Corporation Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted November 19, 2021 CIK No. 0001860742 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences

Consent of John A. Paulson

Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

As filed with the Securities and Exchange Commission on January 13, 2022

Table of Contents As filed with the Securities and Exchange Commission on January 13, 2022 Registration No.

Subsidiaries of the registrant

Exhibit 21.1 ENTITY NAME JURISDICTION Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision SA Argentina Bausch & Lomb (Australia) Pty Ltd Australia Bausch & Lomb Australia Holdings Pty Ltd. Australia Bausch & Lomb GmbH Austria Bausch Health LLC Belarus Bausch & Lomb Pharma S.A. Belgium BL Ind?stria ?tica Ltda. Brazil 9079-8851 Qu?bec, Inc. Canada Beijing Bausch & Lomb Eyecare Company Ltd China S

Form of By-laws of Bausch + Lomb to be effective at closing

Exhibit 3.3 BY-LAW NO. 2021-1 a by-law relating generally to the transaction of the business and affairs of BAUSCH + LOMB CORPORATION (the ?Corporation?) ARTICLE 1 DEFINITIONS AND PRINCIPLES OF INTERPRETATION 1.1 Definitions In this By-law and all other By-laws of the Corporation, unless the context indicates otherwise: (a) ?Act? means the Canada Business Corporations Act or any statute which may

Consent of Richard U. De Schutter

Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

Consent of Thomas W. Ross, Sr.

Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Bausch+Lomb Corporation of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bausch+Lomb Co

LETTER

United States securities and exchange commission logo December 1, 2021 Joseph C. Papa Chief Executive Officer Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 Re: Bausch + Lomb Corporation Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted November 19, 2021 CIK No. 0001860742 Dear Mr. Papa: We have reviewed your amended draft registration stateme

Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on November 19, 2021. This draft registration statement has not been publicly fil

Table of Contents Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.

Michael Kaplan

DRSLTR 1 filename1.htm Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 November 19, 2021 Re: Bausch + Lomb Corporation Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted September 3, 2021 CIK No. 0001860742 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance

LETTER

United States securities and exchange commission logo September 17, 2021 Joseph C.

Michael Kaplan

Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 September 3, 2021 Re: Bausch + Lomb Corporation Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted September 3, 2021 CIK No. 0001860742 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences

Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on September 3, 2021. This draft registration statement has not been publicly fil

DRS/A 1 filename1.htm Table of Contents Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on September 3, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Regis

Michael Kaplan

Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 August 6, 2021 Re: Bausch + Lomb Corporation Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted July 9, 2021 CIK No. 0001860742 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences U.S. Se

LETTER

United States securities and exchange commission logo July 19, 2021 Joseph C. Papa Chief Executive Officer Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 Re: Bausch + Lomb Corporation Amendment No. 1 to Draft Registration Statement on Form S-1 July 9, 2021 CIK No. 0001860742 Dear Mr. Papa: We have reviewed your amended registration statement and have the followin

Michael Kaplan

DRSLTR 1 filename1.htm Michael Kaplan +1 212 450 4111 [email protected] davispolk.com Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 July 9, 2021 Re: Bausch + Lomb Corporation Draft Registration Statement on Form S-1 Submitted May 27, 2021 CIK No. 0001860742 CONFIDENTIAL Mr. David Gessert Mr. Tim Buchmiller Division of Corporation Finance Office of Life Sciences U.S.

Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on July 9, 2021. This draft registration statement has not been publicly filed wi

Table of Contents Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.

LETTER

United States securities and exchange commission logo June 24, 2021 Joseph C. Papa Chief Executive Officer Bausch + Lomb Corporation 520 Applewood Crescent Vaughan, Ontario, Canada L4K 4B4 Re: Bausch + Lomb Corporation Draft Registration Statement on Form S-1 Submitted May 27, 2021 CIK No. 0001860742 Dear Mr. Papa: We have reviewed your draft registration statement and have the following comments.

Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on May 27, 2021. This draft registration statement has not been publicly filed wi

Table of Contents Confidential Treatment Requested by Bausch + Lomb Corporation Pursuant to 17 C.